Merck (MRK) Depreciation & Amortization (CF) (2009 - 2020)

Merck (MRK) has reported Depreciation & Amortization (CF) for 12 consecutive years, with $395.0 million the latest figure, recorded in Q3 2020.

• On a quarterly basis, Depreciation & Amortization (CF) rose 3.4% year-over-year to $395.0 million in Q3 2020; TTM through Jun 2021 was $395.0 million, a 84.38% decrease from a year earlier, with the FY2019 full-year figure at $3.7 billion, down 19.19% from the prior year.
• Depreciation & Amortization (CF) was $395.0 million for Q3 2020 at Merck, up from $390.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.6 billion in Q1 2016 and troughed at $324.0 million in Q3 2018.
• A 5-year average of $716.6 million and a median of $438.0 million in 2016 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) retreated 24.2% in 2017 and gained 28.61% in 2019, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.2 billion in 2016, then slipped by 1.52% to $1.2 billion in 2017, then fell by 14.48% to $998.0 million in 2018, then fell by 6.21% to $936.0 million in 2019, then sank by 57.8% to $395.0 million in 2020.
• The last three Depreciation & Amortization (CF) figures came in at $395.0 million (Q3 2020), $390.0 million (Q2 2020), and $821.0 million (Q1 2020), per Business Quant data.